多重耐药铜绿假单胞菌感染治疗药物研究进展
Research advances of antibiotics on multidrug-resistant Pseudomonas aeruginosa infections
吕鹏 1张京莉 1赵泓 1王运红 1马芬芬 2张玉 3黄怡菲3
作者信息
- 1. 太和县人民医院药剂科,安徽阜阳 236600
- 2. 复旦大学附属浦东医院临床药学室,上海 201399
- 3. 华中科技大学同济医学院附属协和医院药学部,湖北武汉 430022
- 折叠
摘要
多重耐药铜绿假单胞菌(Pseudomonas aeruginosa,PA)是院内感染的常见病原体之一,可同时通过多种耐药机制对常见抗菌药物产生耐药性,显著增加感染治疗难度和患者死亡率,已成为全球公共卫生难题.本文综述了 PA感染的流行病学、危险因素及对常用抗菌药物的耐药特性,分析多重耐药PA感染治疗药物头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦、亚胺培南-西司他汀/雷巴坦及头孢地尔的敏感性判定标准及其临床应用,以期为临床应用提供参考.
Abstract
Multidrug-resistant Pseudomonas aeruginosa has become one of the common pathogens of nosocomial infections.It can simultaneously develop resistance to common antibiotics through multiple resistance mechanisms.Increasing treatment difficul-ties and patient mortality significantly,it has become a global public health challenge.This review focused upon the epidemiologi-cal features and risk factors of Pseudomonas aeruginosa infection,the resistance characteristics to commonly used antibiotics and analyzes the sensitivity criteria and clinical applications of new antibiotics against multidrug-resistant Pseudomonas aeruginosa including ceftolozane/tazobactam,ceftazidime/avibactam,imipenem-cilastatin/relebactam and cefiderocol.It may provide refer-ences for clinical applications.
关键词
新型抗菌药物/多重耐药铜绿假单胞菌/临床应用Key words
novel antibacterial drugs/Multidrug-resistant Pseudomonas aeruginosa/clinical application引用本文复制引用
基金项目
国家重点研发计划(2017YFC0909900)
国家自然科学基金青年科学基金(81900224)
出版年
2024
NETL
NSTL
万方数据